CO6721014A2 - Péptido antitumoral derivado de una región determinante de complementariedad de un anticuerpo monoclonal humanizado al transportador napi2b - Google Patents

Péptido antitumoral derivado de una región determinante de complementariedad de un anticuerpo monoclonal humanizado al transportador napi2b

Info

Publication number
CO6721014A2
CO6721014A2 CO13142398A CO13142398A CO6721014A2 CO 6721014 A2 CO6721014 A2 CO 6721014A2 CO 13142398 A CO13142398 A CO 13142398A CO 13142398 A CO13142398 A CO 13142398A CO 6721014 A2 CO6721014 A2 CO 6721014A2
Authority
CO
Colombia
Prior art keywords
monoclonal antibody
determining region
humanized monoclonal
complementarity determining
peptide derived
Prior art date
Application number
CO13142398A
Other languages
English (en)
Inventor
Luiz Rodolfo Raja Cabaglia Travassos
Original Assignee
Recepta Biopharma S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recepta Biopharma S A filed Critical Recepta Biopharma S A
Publication of CO6721014A2 publication Critical patent/CO6721014A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/10—Bryophyta (mosses)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen péptidos nuevos aislados o sintéticos derivados de una secuencia de aminoácidos de un dominio híper-variable en una región determinante de complementariedad del anticuerpo monoclonal humanizado al transportador NaPi2B, como también derivados de los mismos, y un compuesto farmacéutico y un método para inhibir el crecimiento de tumores o tratar un tumor o cáncer utilizando los péptidos antitumorales o sus derivados.
CO13142398A 2010-12-14 2013-06-14 Péptido antitumoral derivado de una región determinante de complementariedad de un anticuerpo monoclonal humanizado al transportador napi2b CO6721014A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42285610P 2010-12-14 2010-12-14

Publications (1)

Publication Number Publication Date
CO6721014A2 true CO6721014A2 (es) 2013-07-31

Family

ID=46245158

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13142398A CO6721014A2 (es) 2010-12-14 2013-06-14 Péptido antitumoral derivado de una región determinante de complementariedad de un anticuerpo monoclonal humanizado al transportador napi2b

Country Status (8)

Country Link
US (2) US9193797B2 (es)
EP (1) EP2654769B1 (es)
JP (1) JP6087289B2 (es)
BR (1) BR112013015001B1 (es)
CO (1) CO6721014A2 (es)
ES (1) ES2804476T3 (es)
PT (1) PT2654769T (es)
WO (1) WO2012080822A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2929565A1 (en) * 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
CN105491524B (zh) * 2015-12-11 2019-04-26 小米科技有限责任公司 一种确定目标便携设备位置的方法和装置
WO2019006529A2 (en) * 2017-07-01 2019-01-10 Recepta Biopharma S A IMMUNOMODULATORY PEPTIDES AND MODULATION METHODS
CA3075798A1 (en) * 2017-09-20 2019-03-28 Mersana Therapeutics, Inc. Compositions and methods for predicting response to napi2b-targeted therapy
CN116514926B (zh) * 2023-06-25 2023-08-29 烟台药物研究所 一种抗肿瘤阳离子两亲肽及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9108652D0 (en) * 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
AU684348B2 (en) * 1994-06-07 1997-12-11 Nihon Medi-Physics Co., Ltd. Tumor affinity peptide, and radioactive diagnostic agent and adioactive therapeutic agent containing the peptide
US6689753B1 (en) 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
JP2007534631A (ja) * 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
EP2250201B1 (en) * 2008-01-29 2014-04-30 Ludwig Institute for Cancer Research Ltd. Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

Also Published As

Publication number Publication date
ES2804476T3 (es) 2021-02-08
JP6087289B2 (ja) 2017-03-01
PT2654769T (pt) 2020-07-16
US9193797B2 (en) 2015-11-24
BR112013015001B1 (pt) 2021-10-13
BR112013015001A8 (pt) 2018-04-17
BR112013015001A2 (pt) 2017-12-19
EP2654769A4 (en) 2017-10-25
JP2014510699A (ja) 2014-05-01
US9896512B2 (en) 2018-02-20
WO2012080822A2 (en) 2012-06-21
WO2012080822A9 (en) 2016-08-11
US20130315902A1 (en) 2013-11-28
EP2654769B1 (en) 2020-04-15
EP2654769A2 (en) 2013-10-30
US20160108132A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
CY1120471T1 (el) Αντισωματα κατα του cd70
DOP2021000023A (es) Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr
EA202092410A1 (ru) Конъюгаты камптотецина с пептидом
UY36404A (es) ANTICUERPOS MONOCLONALES (Ab) COMO DETECTORES DE CD73 E INHIBIDORES DE SU ACTIVIDAD ENZIMÁTICA, Y COMPOSICIONES QUE LOS CONTIENEN
MX352738B (es) Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos.
CR20180519A (es) Neoantígenos y métodos de su uso
NI201500024A (es) Anticuerpos y vacunas para utilizarse en el tratamiento de cánceres por ror1 y para inhibir la metástasis.
EA201391509A1 (ru) Твердофазные формы кабазитаксела и способы их получения
CO2017001023A2 (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
BR112017000316A2 (pt) ?anticorpo, imunoconjugado, composição, construção de ácido nucleico, vetor de expressão, hibridoma, métodos para tratamento de câncer, para diagnosticar uma doença, inibir crescimento e/ou proliferação de um tumor de célula e produzir um anticorpo, uso, e, kit?
MX2016014189A (es) Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antigeno 4 de linfocito t citotoxico (anti-ctla-4) para tratar el cancer de pulmon no microcitico.
MX370818B (es) Anticuerpos anti-b7-h1 para tratar tumores.
CY1122456T1 (el) Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
PE20141271A1 (es) Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
AR096687A1 (es) Anticuerpos anti-fcrh5
EP4223874A3 (en) Human anti-il-33 neutralizing monoclonal antibody
EA201491006A1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
EA201490039A1 (ru) Химерные и гибридные полипептиды фактора viii и способы их применения
BR112012021327B8 (pt) anticorpo monoclonal anti-her2 humanizado, método de preparação e uso do mesmo.
EA201391389A1 (ru) Кристаллы антител против склеростина и составы на их основе
AR087567A1 (es) Anticuerpos anti-tie2 y usos de los mismos
BR112012011528A2 (pt) métodos para inibir uma proteína quinase e para tratar uma doença associada com atividade de quinase, e, composto